Provided By GlobeNewswire
Last update: Jun 25, 2025
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Read more at globenewswire.comNASDAQ:APRE (11/13/2025, 1:00:32 PM)
1.2101
-0.05 (-3.96%)
Find more stocks in the Stock Screener


